Cost-effectiveness of BRCA1 testing at time of obstetrical prenatal carrier screening for cancer prevention

Improved technologies paired with an increase in access to genetic testing has led to the availability of expanded carrier screening evaluating hundreds of disorders. Currently, most autosomal dominant mutations, such as BRCA1, are not included in expanded carrier assays. Screening pregnant or preconception reproductive-aged women for BRCA1 may present a unique opportunity to perform population-based screening for patients at a time where precancer screening, chemoprevention and/or risk reducing surgery may be beneficial.

Source: American Journal of Obstetrics and Gynecology - April 13, 2024 Category: OBGYN Authors: Shayan M. DIOUN, Luiza R. PEREZ, Malavika PRABHU, Jesse T. BREWER, Muhammad D. AHSAN, June Y. HOU, Ravi N. SHARAF, Jason D. WRIGHT, Melissa K. FREY Tags: Original Research: Obstetrics Source Type: research